Press Releases 
arGentis Acquires Rights To Rheumatoid Arthritis Therapy
arGentis Pharmaceuticals, LLC announces it will collaborate with the University of Tennessee Health Science Center and the Veterans Affairs Medical Center of Memphis to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.
arGentis Expands Scientific Advisory Board
Maureen D. Mayes, MD, Daniel E. Furst, MD, Virginia D. Steen, MD and Weng Kee Wong, PhD have joined arGentis' Scientific Advisory Board and will lend their expertise to the company in the clinical development of ARG201 for Systemic Sclerosis.
arGentis Files Patent on Nucleic Acid Sequences and Polymorphisms Predictive of Patient Responses to ARG201, an Immunotherapy for Late Phase Systemic Sclerosis
Results from patient DNA samples from a 168-patient, double-blind Phase II trial indicate that 30% of systemic sclerosis patients have a specific nucleotide polymorphism (SNP). This same group of patients did not appear to respond to oral collagen therapy. Approximately 70% of patients did respond to ARG201 therapy. That group did not appear to carry the SNP.
Phase II Results for Low-Dose Oral Immune Tolerance Therapy (ARG201) in Systemic Scleroderma Published
The article reviews the results of the 168-patient, twelve center trial in which patients were administered a precise dose of highly purified type 1 collagen or placebo for 12 months with follow up at 15 months.
arGentis Licenses Third Treatment for Dry Eye Syndrome
arGentis™ Pharmaceuticals announces the company has licensed a third treatment for Dry Eye Syndrome (DES).
Innova Memphis Inc. Invests In arGentis Pharmaceuticals
Innova Memphis Inc. announced today it has invested in arGentis™ Pharmaceuticals LLC, a specialty pharmaceutical company based in Memphis.
arGentis Receives Orphan Drug Designation
arGentis Pharmaceuticals, LLC announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's product candidate ARG201 (native type 1 bovine collagen) for the treatment of diffuse systemic sclerosis, also known as systemic scleroderma (SSc). SSc is a debilitating and fatal autoimmune disease.
arGentis Signs Agreement with LifeCyte to Develop cGMP Facility
arGentis(tm) Pharmaceuticals, LLC announced today that it had signed an agreement with LifeCyte Inc., a Memphis-based biopharmaceutical services company, to assist in the design and development of a dedicated current Good Manufacturing Practices (cGMP) facility that will purify arGentis' collagen products portfolio.
Dr. William E. Cochran joins arGentis Board of Directors
arGentis Pharmaceuticals, LLC announces the appointment of Dr. William E. Cochran as an Executive Officer of the Company and that he will serve on its Board of Directors.
